Recently Released Market Study: Philippines Pharmaceuticals & Healthcare Report Q4 2012
BMI View: Access to healthcare will continue to be limited by poor drug-pricing legislation in the Philippines. Although this has negative implications for patients, there remain short-term revenue growth opportunities for pharmaceutical firms, distributors and retailers, given the higher mark-ups achieved on medicines. Importantly, we caution that such ineffectiveness will also prevent the country from implementing universal healthcare coverage by 2016, unless it can properly address the issue of drug affordability. Over the longer term, we anticipate improvements to the...
View full press release